On October 5, 2025, a promising initiative aimed at analyzing the factors influencing participation in clinical research protocols for oncology was announced by the University Hospital Center of Martinique (CHUM) in collaboration with the KaFE Association. This study, titled ‘StudyOrec,’ seeks to uncover the determinants driving both patients and healthcare professionals to engage in cancer-related studies. Though not yet recruiting, the study has garnered attention for its focus on qualitative interviews and quantitative surveys to collect valuable insights.
What is the purpose of this study?
The primary objective of StudyOrec is to understand the motivations and barriers affecting participation in clinical research protocols within medical oncology. By gathering data directly from patients dealing with oncologic diseases and the healthcare professionals treating them, researchers aim to uncover trends, gaps, and actionable solutions that may enhance clinical trial inclusivity and efficacy. Addressing these determinants is critical for advancing oncology treatments and improving patient outcomes.
What methods will be used?
StudyOrec employs a dual-method approach:
- Semi-Structured Patient Interviews: Patients diagnosed with cancer will provide qualitative insights into their experiences, perceptions, and motivations for joining or declining clinical studies.
- <strong Healthcare Professional Questionnaires: Medical staff, including oncologists, nurses, and allied health professionals, will answer focused quantitative surveys designed to assess their viewpoint, professional constraints, and suggestions regarding research participation.
This comprehensive framework ensures a balanced view of the challenges and enablers at both patient and provider levels.
How could this study impact oncology research?
The findings from StudyOrec have significant potential to influence both policy and practice:
- By illuminating patient-specific challenges, healthcare systems can refine strategies and tailor communication efforts aimed at improving enrollment in oncology trials.
- Healthcare professionals’ feedback will shed light on systemic and operational improvements that could facilitate their involvement in clinical protocols.
- The study may provide actionable recommendations for ensuring ethical and streamlined processes that align with MDR (Medical Device Regulations) standards, fostering trust and reliable outcomes for stakeholders.
These outcomes could bolster the success rates and overall impact of oncology research worldwide.
Frequently Asked Questions
- When is recruitment starting?
Recruitment has not yet begun. Updates will be shared via the official registry and sponsor channels. - Who can participate?
Patients with oncologic diseases and healthcare professionals working within oncology departments will be eligible for this study. - How will the data be used?
The collected data will be analyzed to identify patterns and insights that could influence future clinical trial processes and improve protocol design.
Key Takeaways for Professionals
StudyOrec represents an important step toward optimizing oncology research through a deeper understanding of participant dynamics. Clinicians, trial coordinators, and regulatory professionals should watch this space for insights that can improve participation rates and ensure more robust study designs.
The multidisciplinary approach—bridging both qualitative and quantitative methods—is expected to yield actionable guidance for stakeholders. Professionals in regulatory affairs and oncology care may want to align their practices with the outcomes of this initiative.
Disclaimer
This blog post is for informational purposes only and does not constitute legal or medical advice. Readers are encouraged to consult official regulatory guidelines and professional advisors for specific questions.
Announcement Reference
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07206927?term=medical+device